Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008

Journal of the Pancreas

Volumn 9, Issue 2, 2008, Pages 91-98

  Saif, Muhammad Wasif ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Antibodies, monoclonal; Bevacizumab; Capecitabine; Cetuximab; Erlotinib; Fluorouracil; Gemcitabine; Irinotecan; Pancreatic Neoplasms; Protein kinase inhibitors; Protein tyrosine kinase; Receptor, epidermal growth factor; S 1 (combination)

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CHINESE DRUG; CISPLATIN; ERLOTINIB; EXATECAN; FLUOROURACIL; GEMCITABINE; GENEXOL PM; IRINOTECAN; LONAFARNIB; OXALIPLATIN; PACLITAXEL; PHY 906; TANOMASTAT; VOLOCIXIMAB;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG POTENTIATION; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LEUKOPENIA; LUNG EMBOLISM; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PNEUMONIA; PRACTICE GUIDELINE; PROGERESSION FREE SURVIVAL; RASH; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; HUMANS; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 42949130589     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Rubin J, Gallagher JG, Schroeder G, Schutt AJ, Dalton RJ, Kugler JW, et al. Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer 1996; 78:1888-91.
2. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985; 253:2061-7.
3. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73:101-5.
4. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, et al. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12:29-34.
5. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with genicitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
6. Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21:3296-302.
7. Cheverton P, Friess H, Andras C, Salek T, Geddes C, Bodoky P, et al. Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-nalve patients with advanced pancreatic cancer (APC). J Clin Oncol 2004; ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Suppl):4005.
8. Lersch C, van Cutsem E, Amado R, Ehninger G, Heike M, Kerr D, et al. Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 20: 2001. Abstract No: 608.
9. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Bowen Benson A 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients With advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20:3270-5.
10. Reiss H, Helm A, Niedergethmann M, SchmidtWolf I, Moik M, Hammer C, et al. A randomized, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; ASCO Annual Meeting Proceedings. Vol 23, No 16S (June 1 Suppl):LBA4009.
11. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, et al. Gemicitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25:2212-7.
12. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemicitabine monotherapy in patients with locally advanced or metastatic pacreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22:377643.
13. Louvet C, Labianca I, Hammel P, Lledo G, Zampino MG, Andre T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-16.
14. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, et al. Randomized phase III trial of gemicitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24:3946-521.
15. Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B), versus gemicitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis od Cance and Leukemia Group B (CALGB) 80303. ASCO Gastrointestinal Cancers Symposium 2007. Abstract No: 108.
16. Philip PA, Benedetti J, Fenoglio-Preiser C, Zalupski M, Lenz; H, O'Reilly E, et al. Phase III study of gemcitabine, [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG SO2O5 study. J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Suppl): LBA4509.
17. Cunningham D, Chau I, Stocken C, Davies C, Dunn J, Valle J, et al. Phase III randomized comparison of gemicitabine (GEM) versus gemicitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer Suppl 2005; 3:12. Abstract PS11.
18. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J Clin Oncol 2005; 23(16S part I). Abstract No: 1.
19. Evans T, Valle J, Berlin J, Glynne-Jones R, Anthoney D, Huang R, et al. Interim results from a phase II study of volociximab in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC). 2008 Gastrointestinal Cancers Symposium. Abstract No: 142.
20. Oh D, Choi I, Yoon S, Choi I, Kim J, Oh S, et al. A multicenter phase II study of gemcitabine and S-1 combination chemoterapy in patients with unresectable pancreatic cancer. 2008 Gastrointestinal Cancers Symposium. Abstract No: 212.
21. Shitara K, Komatsu Y, Yuki S, Munakata. M, Muto O, Shimaya S, Sakata Y. Pilot study of combination chemotherapy with S-1 and irinotecan (IRIS) for advanced pancreatic cancer. 2008 Gastrointestinal Cancers Symposium. Abstract No: 155.
22. Blaszkowsky LS, Zhu AX, Abrams T, Clark JW, Earle C, Kwak E, et al. A phase II study of gemcitabine (GEM), bevacizzumab (BEV), and erlotinib (E) in locally advanced and metastatic adenocarcinoma of the pancreas. 2008 Gastrointestinal Cancers Symposium. Abstract No: 151.
23. Iyer RV, Yu J, Garrett CR, Litwin AM, Kuvshinoff B, Tarquini M, et al. Gemcitabine, capecitabine and bevacizumab in patients with advanced pancreatic cancer (APC): Final results of the multicenter phase II study. 2008 Gastrointestinal Cancers Symposium. Abstract No: 198.
24. Starling N, Watkins. D, Chau I, Norman A, Fairhead E, Thomas J, et al. A phase I study of a chemotherapy doublet (gemcitabine plus capecitabine [GemCap]), combined with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma (PC): The TARGET Trial. 2008 Gastrointestinal Cancers Symposium. Abstract No: 141.
25. Saif, MW, Rubin MS, Figueroa JA, Kerr RO. Multicenter phase II trial of Genexol-PM (GPM), a novel Cremophor-free, polymeric micelle formulation of paclitaxel in patients with advanced pancreatic cancer (APC): Final results. 2008, Gastrointestinal Cancers Symposium. Abstract No: 269.
26. Saif MW, Liu S, Elfiky A, Jiang Z, Cheng Y. Synergistic activity of PHY906 with capecitabine in pancreatic carcinoma. J Clin Oncol 2007; ASCO Annual-Meeting Proceedings Pait 1. Vol 25, No. 18S (June 26 Supplement), 2007: 15116.
27. Hoimes CJ, Lamb L, Elligers K, Mezes M, Grant N, Ruta S, et al. A phase I/II study of PHY906 plus capecitabine (CAP) in patients (pts) with advanced pancreatic carcinoma (PC). 2008 Gastrointestinal Cancers Symposium. Abstract No: 260.
28. Saif MW. Pancreatic cancer: highlights rom the 42nd annual meeting of the American Society of Clinical Oncology, 2006. JOP. J Pancreas (Online) 2006; 7:337-48.